- Our Work
- Get Involved
Amita Gupta, MD, MHS
Professor of Medicine and Public Health
Dr. Gupta is Deputy Director of the Johns Hopkins (JH) Center for Clinical Global Health Education (CCGHE), and Professor of Infectious Diseases at the JH School of Medicine, with a joint appointment in International Health at the JH Bloomberg School of Public Health.
Board certified by the American Board of Internal Medicine in infectious diseases, Dr. Gupta specializes in international public health, clinical research, and education in infectious diseases, HIV/AIDS, tuberculosis (TB), and antimicrobial resistant infections. Since 2003, her work has been focused primarily on India, where she leads several Indo-JHU research collaborations. She serves in leadership positions as Center Director for the Johns Hopkins Precision Medicine Center for Excellence for COVID-19, the US chair for the Indo-US Vaccine Action Program sponsored RePORT India TB research consortium, which is funded by the US National Institutes of Health (NIH) and the government of India, Department of Biotechnology. She also serves on the global RePORT International Executive Committee, a multilateral global consortia for TB research. She is Co-principal Investigator of the NIH-funded Baltimore-Washington-India HIV and Infectious Diseases Clinical Trials Unit (BWI-CTU), and she is an active clinical investigator in multi-country trials conducted by the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Trials Network (IMPAACT), and has served as protocol chair for high impact studies that have resulted in publications in The New England Journal of Medicine and The Lancet. She is Co-chair of the NIH and AmFAR funded IeDea HIV/TB Working Group and Scientific Committee co-Chair for IMPAACT TB.
She has been awarded research grants from the NIH, CDC, UNITAID, and several philanthropic foundations to investigate infectious diseases of importance to India and beyond. Learn about CCGHE India Research Partnerships In 2019, Dr. Gupta was appointed by the US Health and Human Services Secretary for a 4-year term to the NIAID Council, the chief advisory committee for National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health. In 2020, she was invited to the Governing Board of the Indo-U.S. Science & Technology Forum.
Dr. Gupta is an author of more than 200 peer-reviewed research publications and 7 book chapters on prevention and treatment of HIV, TB, and other infectious diseases, primarily in low- and middle-income settings. She has also mentored more than 35 junior scientists in India and the US to run research studies and submit their own scientific findings to peer-reviewed publications.
Dr. Gupta received an undergraduate degree from MIT, a Doctor of Medicine from Harvard Medical School, and a Master of Health Sciences in clinical investigation from JH Bloomberg School of Public Health. She completed her internal medicine training at San Francisco General Hospital-University of California, San Francisco, followed by a post-doctoral fellowships with the Epidemic Intelligence Service at the US Centers for Disease Control and Prevention (CDC, Foodborne and Diarrheal Diseases) and at the JHU School of Medicine (Infectious Diseases).
Research Program Building and Leadership
- 2007-present: Chair, IMPAACT P1078, A Randomized Clinical Trial to Evaluate the Safety of Immediate (antepartum-initiated) Versus Deferred Reduction in TB Incidence and Mortality Among HIV-Infected Women and Their Infants in High TB Incidence Settings
- 2008-present: Protocol Vice-Chair of ACTG 5274, Reducing Early Mortality Among Patients with Advanced HIV Disease: A Randomized Strategy Trial Comparing the Safety and Efficacy of an Individualized Patient TB Treatment Approach to a Public Health Pre-emptive TB Treatment Approach in Resource-Limited Settings (REMEMBER)
- 2008-2012: Co-investigator ACTG 5267, A Phase I, Safety, Tolerability, and Pharmacokinetic Interaction Study of Single-Dose TMC207 and Efavirenz in Health Volunteers
- 2008-2012: Co-investigator ACTG 5253 Sensitivity and Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals
- 2009-present: Protocol Vice Chair ACTG 5279, Phase III Clinical Trial of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Adults with Latent Tuberculosis Infection
- 2010: Invited by NIAID, NIH to be a part of a NIH delegation to assess scope of TB research in India. Accompanied the Deputy Director of the Division of AIDS, the Associate Director of International Health Programs, NIAID and other NIH delegates on site visits to 15 Indian institutions throughout the country
- 2011-2012: Selected to participate in the Johns Hopkins School of Medicine’s Office in Science and Medicine (OWISM) Leadership Program for Women Faculty
- 2012-present: Member, ACTG TB Transformative Science Group
- 2014-present: IMPAACT TB Scientific Committee Vice-Chair
- 2014-present: Co-investigator IMPAACT 2001 Protocol Team, PK and Safety of INH and Rifapentine in Pregnancy
- 2014-2016: US Co-chair, NIH-India Government, Regional Prospective Observational Research in Tuberculosis (RePORT)
- 2014-present: Co-chair PHOENIX ACTG A5300/IMPAACT 2003 feasibility study and MDR TB contact prophylaxis trial
- 2016-present: US Chair, TB Research Consortium, RePORT India
- 2016-present: Member, Executive Committee, RePORT International
- 2017: Selected to participate in the Johns Hopkins Leadership Development Program (LDP)
- 2015-present: Member, Union Interest Group in Maternal-Infant TB working group
- 2018: Participant, Technical Consultation on Advances in Clinical Trial Design for Development of New TB Treatments, WHO Report generation
- 2018-present: co Chair, IeDEA TB working group
- 2019-present: NIAID Council
- 2020-present: Governing Board Member, Indo-US Science and Technology Forum (IUSTTF)
- 2020-present: Chair, Faculty Steering Committee, Johns Hopkins India Institute
- 2020-present: Center Director, Johns Hopkins Precision Medicine Center for Excellence for COVID-19